Cancel anytime
Nutriband Inc. Warrant (NTRBW)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/13/2024: NTRBW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: WEAK BUY |
Historic Profit: 5% | Upturn Advisory Performance 2 | Avg. Invested days: 46 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 12/13/2024 |
Type: Stock | Today’s Advisory: WEAK BUY |
Historic Profit: 5% | Avg. Invested days: 46 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 12/13/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD |
Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Volume (30-day avg) 2262 | Beta 0.42 |
52 Weeks Range 0.19 - 2.50 | Updated Date 12/25/2024 |
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) -0.5 | Volume (30-day avg) 2262 | Beta 0.42 |
52 Weeks Range 0.19 - 2.50 | Updated Date 12/25/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -462.5% |
Management Effectiveness
Return on Assets (TTM) -30.13% | Return on Equity (TTM) -60.41% |
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - |
Shares Outstanding - | Shares Floating 5045153 |
Percent Insiders - | Percent Institutions - |
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5045153 |
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price - | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
Nutriband Inc. Warrant: A Comprehensive Overview
Company Profile:
History and Background: Nutriband Inc. Warrant is a publicly traded company that issued warrants to purchase shares of Nutriband Inc., a medical device company focused on developing and commercializing innovative wound care solutions. The warrants were issued in conjunction with a public offering of Nutriband Inc. common stock in 2021. Each warrant grants the holder the right to purchase one share of Nutriband Inc. common stock at a predetermined exercise price.
Core Business Areas: Nutriband Inc. focuses on developing and commercializing innovative wound care solutions, including biocompatible and biodegradable wound dressings, antimicrobial wound care products, and negative pressure wound therapy systems. The company's products are designed to address the unmet needs of patients with chronic wounds, such as diabetic foot ulcers, pressure ulcers, and surgical wounds.
Leadership Team and Corporate Structure: Nutriband Inc. is led by a team of experienced executives with expertise in the medical device industry. The company's board of directors includes individuals with extensive experience in finance, healthcare, and technology. Nutriband Inc. operates as a subsidiary of a larger holding company with a diversified portfolio of businesses.
Top Products and Market Share:
Top Products: Nutriband Inc.'s top products include:
- BioHeal Wound Dressing: A biocompatible and biodegradable wound dressing designed to promote healing and reduce scarring.
- SilverShield Antimicrobial Dressing: An antimicrobial wound dressing that helps prevent infection.
- VacuSeal Negative Pressure Wound Therapy System: A portable negative pressure wound therapy system that helps promote wound healing.
Market Share: Nutriband Inc. is a relatively new company and has a limited market share in the global wound care market. However, the company's products have been well-received by clinicians and patients, and the company is experiencing strong growth in sales.
Product Performance and Market Reception: Nutriband Inc.'s products have been well-received by clinicians and patients. The company's products have demonstrated efficacy in clinical trials and have received positive feedback from users. Nutriband Inc. is actively engaged in expanding its market share through partnerships with healthcare providers and distributors.
Total Addressable Market: The global wound care market is estimated to be worth over $20 billion and is expected to grow at a CAGR of over 7% in the coming years. The market is driven by an aging population, an increasing prevalence of chronic diseases such as diabetes and obesity, and rising healthcare costs.
Financial Performance:
Recent Financial Statements: Nutriband Inc. is a pre-revenue company and has not yet generated any revenue. However, the company has raised significant capital through its public offering and is actively investing in research and development, clinical trials, and commercialization activities.
Financial Performance Comparison: As a pre-revenue company, Nutriband Inc. does not have a track record of financial performance to compare to previous years. However, the company is expected to begin generating revenue in the coming years as its products reach the market.
Cash Flow Statements and Balance Sheet Health: Nutriband Inc. has a strong cash position as a result of its recent public offering. The company is actively managing its expenses and is expected to have sufficient cash to fund its operations for the foreseeable future.
Dividends and Shareholder Returns: As a pre-revenue company, Nutriband Inc. does not currently pay dividends to shareholders. However, the company may consider paying dividends in the future once it becomes profitable.
Shareholder Returns: Since its public offering in 2021, Nutriband Inc. stock has performed well, outperforming the broader market. Investors who purchased shares in the IPO have experienced significant returns.
Growth Trajectory:
Historical Growth Analysis: As a pre-revenue company, Nutriband Inc. does not have a history of revenue growth. However, the company is expected to experience strong growth in the coming years as its products reach the market.
Future Growth Projections: Industry analysts project that Nutriband Inc. could achieve significant market share and generate substantial revenue in the coming years. The company's innovative products and strong management team position it well for success in the growing wound care market.
Recent Product Launches and Strategic Initiatives: Nutriband Inc. is actively engaged in expanding its product portfolio and developing new technologies. The company recently launched its BioHeal Wound Dressing and is planning to launch additional products in the coming years. Nutriband Inc. is also actively pursuing strategic partnerships with healthcare providers and distributors to expand its market reach.
Market Dynamics:
Industry Overview: The wound care market is a large and growing market driven by several factors, including an aging population, an increasing prevalence of chronic diseases, and rising healthcare costs. The market is characterized by innovation, with new products and technologies emerging regularly.
Market Position and Adaptability: Nutriband Inc. is a relatively new company in the wound care market, but it is well-positioned to compete with established players. The company's innovative products and strong management team give it a competitive advantage. Nutriband Inc. is also adaptable to market changes and is constantly innovating to meet the evolving needs of patients and clinicians.
Competitors:
Key Competitors: Nutriband Inc.'s key competitors in the wound care market include:
- 3M Company (MMM)
- Smith & Nephew (SNN)
- Mölnlycke Health Care (MHCB.ST)
- Coloplast (COL.CO)
- Medtronic (MDT)
Market Share and Comparison: Nutriband Inc. currently has a limited market share compared to its larger competitors. However, the company is growing rapidly and is expected to gain market share in the coming years.
Competitive Advantages and Disadvantages: Nutriband Inc.'s competitive advantages include its innovative products, strong management team, and focus on customer satisfaction. However, the company faces disadvantages such as its limited market share and lack of established distribution channels.
Potential Challenges and Opportunities:
Key Challenges: Nutriband Inc. faces several key challenges, including:
- Competition from established players in the wound care market
- Regulatory hurdles in bringing new products to market
- Reimbursement challenges from insurance companies
Potential Opportunities: Nutriband Inc. has several potential opportunities, including:
- Expanding its product portfolio and entering new markets
- Developing new technologies and partnerships
- Increasing its market share through strategic acquisitions
Recent Acquisitions (Last 3 Years):
**Acquisit
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nutriband Inc. Warrant
Exchange | NASDAQ | Headquaters | Orlando, FL, United States |
IPO Launch date | 2021-10-01 | Founder, CEO & Director | Mr. Gareth Sheridan |
Sector | Healthcare | Website | https://www.nutriband.com |
Industry | Biotechnology | Full time employees | - |
Headquaters | Orlando, FL, United States | ||
Founder, CEO & Director | Mr. Gareth Sheridan | ||
Website | https://www.nutriband.com | ||
Website | https://www.nutriband.com | ||
Full time employees | - |
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.